L'Oréal-Backed Aesthetics Chain Yesskin Named Debtor in Chinese Court Order

Zhejiang Yesskin Technology Co., Ltd., the parent company behind Chinese high-end medical aesthetics chain Yesskin and an investee of L'Oréal Group, has been added to China's public court enforcement database over an unpaid obligation of 881,600 RMB ($123,000 USD).

Unpaid Court Judgment Totaling $123,000

According to China's National Enterprise Credit Information Publicity System, Zhejiang Yesskin Technology was established in April 2011 with a registered capital of 10 million RMB ($1.4 million USD). Its legal representative is listed as Ma Lan, matching the name of the Vice President of L'Oréal China and General Manager of its Dermatological Beauty Division.

Corporate ownership records show Yesskin Technology is 70% owned by Shanghai Yimei Business Consulting Co., Ltd., with founder Song Weimin holding the remaining 30%. Shanghai Yimei is indirectly controlled by Meiding Hong Kong Limited, a wholly owned subsidiary of L'Oréal.

Recent court records from China's public enforcement registry indicate that the Ningbo Haishu District People's Court in Zhejiang Province placed Yesskin Technology on its enforceable debtor list under case number (2026) Zhe 0203 Zhi 6341, seeking enforcement of 881,600 RMB ($123,000 USD).

Named alongside Yesskin Technology in the enforcement order is Ningbo Haishu Yanxi Yuerong Medical Beauty Clinic Co., Ltd.

Yanxi Yuerong was established in January 2021 as a regional franchise clinic for the Yesskin brand in Ningbo. Zhejiang Yesskin Technology served as its founding shareholder and gradually increased its stake to 100% in April 2023. However, Yesskin fully divested from the clinic in May 2024, transferring complete ownership to two individual investors, Yuan Yongzhen (90%) and Zhu Guoxing (10%).

Although Yesskin Technology no longer holds equity in Yanxi Yuerong, the joint court order suggests the enforcement action stems from liabilities or legal disputes incurred while the two entities were affiliated.

Commenting on the legal status, Shen Youfu, a partner at Beijing-based Dao Ke Te Law Firm, explained that a court debtor designation occurs when a party fails to fulfill a legally binding judgment or arbitral award within the designated timeframe. Once the prevailing party applies for compulsory enforcement, courts can initiate measures such as asset tracing, freezing, and bank account deductions in accordance with China's laws and regulations. Shen added that the precise sum of 881,600 RMB likely combines the principal court judgment with accumulated statutory interest and late-payment penalties calculated at a daily rate of 0.0175%.

L'Oréal's Strategic Stake in Clinical Aesthetics

Yesskin Technology's origin lies in a physician-led entrepreneurial model. Founder Dr. Song Weimin spent more than two decades at Hangzhou Third People's Hospital, serving as deputy director of dermatology and head of laser cosmetic dermatology, before leaving the public healthcare system in 2011 to launch Yesskin.

Positioned in the mid-to-high-end segment, Yesskin focused on non-surgical aesthetic procedures and skin health management, combining clinical credentials with a scalable franchise model. The concept gained early traction, with its flagship location acquiring over 1,000 members in its first year.

In September 2016, Yesskin expanded from offline clinical services into retail consumer products by launching YESBEGIN, a functional skincare brand focused on skin barrier repair. The move aimed to monetize its clinical authority through high-margin over-the-counter products.

Institutional investment followed in early 2018 when Yesskin secured tens of millions of RMB in Series A funding from Jianyi Capital (formerly Sinopharm Capital). Rather than pursuing rapid physical expansion, Yesskin allocated the capital toward developing AI-powered skin diagnostic systems and consolidating its presence across East China's Yangtze River Delta region.

A major strategic milestone occurred in 2024 when L'Oréal Group acquired a strategic stake in Yesskin. L'Oréal noted at the time that the investment was designed to establish an operational testing ground for "integrated skincare"—combining medical aesthetics procedures with topical clinical formulations—primarily supporting its core dermatological brand SkinCeuticals. This investment comes amid a broader restructuring among international beauty giants in China, as seen when Lancôme closed its Beijing flagship store to adjust its physical footprint.

Today, Yesskin operates across five business divisions: YESSKIN Clinics, YESAFE Medical Beauty, YesBegin skincare, CSKIN Technology, and YESSHARE Education. Its offline network encompasses 22 clinics across 13 Chinese cities. Its product arm, YESBEGIN, spans dermatological skincare, medical device products, and professional aesthetic equipment to cover both clinical treatment and home care routines.

However, YESBEGIN's e-commerce performance has shown signs of slowing. On Chinese e-commerce platform Tmall, YESBEGIN's flagship store holds 90,000 followers, with its best-selling ceramide cream recording over 1,000 unit sales per listing. On Douyin, TikTok's Chinese sister app, the official store has 874 followers, with the same product achieving over 2,000 sales per listing.

Third-party e-commerce tracking data indicates that YESBEGIN's annual sales across major Chinese online platforms rose from 2.36 million RMB ($329,000 USD) in 2021 to peak at 4.27 million RMB ($595,000 USD) in 2023, before declining to 2.26 million RMB ($315,000 USD) in 2024, 2.10 million RMB ($293,000 USD) in 2025, and 717,000 RMB ($100,000 USD) through the first half of 2026.

For Yesskin, resolving outstanding legal liabilities and restoring online retail momentum will be critical next steps as it seeks to validate L'Oréal's clinical aesthetics partnership model.